Please enable JavaScript.
Coggle requires JavaScript to display documents.
Managing Novartis - Coggle Diagram
Managing Novartis
NI : NI (39%), Novartis Biochemie ( 30%), gemala (31%)
- Buy stock Kimia Farma, dilusi Gemala (injeksi new capital)
Problem : KF said NO
- Banyak otoritas (Menkes dan Menkeu), KF not decision maker
-
- Change Sandoz Biochemi to Novartis Indonesia
- Ciba-Geigy dilepas ke Ciba specialty chemical company, sisanya diubah ke NI
-
-
problem Henti distribusi (shareholder dan otoritas, kemenkes dan kemendag)
-
Virtual Novartis
2 legal entities, 2 diff accounting systems
2 invoice (Ciba Geigy, Sandoz Biochemie)
why ? for value added tax returns (pengembalian PPN, pengembalian PPH, dan Lap. pajak karyawan)
Erikson assuming 6mo, mundur hingga Juni 98